Proteins and Peptides
23 February 2016
Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology23 February 2016
FibCLOT®, Human Fibrinogen from LFB, Obtains First Marketing Authorisations in Europe22 February 2016
FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide17 February 2016
Endo Announces Initiation of Phase 2B Clinical Trial of Collagenase Clostridium Histolyticum in Cellulite16 February 2016
Novaliq Begins Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease16 February 2016
Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)11 February 2016
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim8 February 2016
Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis4 February 2016
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes4 February 2016
CollPlant Reports Positive Final Trial Results for Vergenix™STR, Indicated for the Treatment of Tendinopathy2 February 2016
Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children30 January 2016
Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation22 January 2016
U.S. FDA Approves BOTOX® (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults22 January 2016
FDA approves new Kyprolis® (carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma21 January 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE® (dalbavancin)20 January 2016
Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis17 January 2016
Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis13 January 2016
ThromboGenics Enrolls First Patient in Phase II CIRCLE TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports